Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2010. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share acquisitions made on September 9, 2010, at a price of £12.71 per Ordinary share through the Company's Share Reward Plan. The transactions involved the following individuals acquiring shares under both the partnership element (personal contribution) and the matching element (Company contribution):
- Mr A P Witty
- Mr J S Heslop
- Mr S M Bicknell
- Mr E J Gray
- Mr S A Hussain
- Mr D S Redfern
- Ms C Thomas
- Mr P J T Vallance
Each individual acquired 10 Ordinary shares under the partnership element and 10 Ordinary shares under the matching element, except where noted in the specific transaction details.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Share price for the transaction was £12.71 per Ordinary share.
- Transactions occurred on September 9, 2010, with notification on September 10, 2010.
- The transactions were executed via the Company's Share Reward Plan.
- Each listed director acquired a total of 20 shares (10 personal, 10 company-matched).
- No financial performance metrics are included in this specific filing.